Regulus Therapeutics Inc.
RGLS
Classifica tra le azioni
#17336
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prezzo delle azioni
$8.16
Ultima sincronizzazione: 2025-06-26
Capitalizzazione di mercato
$234.57M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-56.96%
Paese
US
Scambia Regulus Therapeutics Inc. (RGLS)
Categoria
Healthcare
Utile per Regulus Therapeutics Inc. (RGLS)
Utile nel Mar 2024 TTM: $-466.89M
Secondo gli ultimi rapporti finanziari di Regulus Therapeutics Inc., gli utili attuali della società sono $-466.89M. Nel 2022, la società ha registrato un utile di $18.79M, un aumento rispetto a agli utili del 2021, che erano di $-672.17M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Regulus Therapeutics Inc. dal 2002 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-466.89M | 121.21% |
| 2023 | $-211.06M | -1,222.99% |
| 2022 | $18.79M | -102.80% |
| 2021 | $-672.17M | -2,553.84% |
| 2020 | $27.39M | -122.92% |
| 2019 | $-119.51M | 71.97% |
| 2018 | $-69.50M | -15.80% |
| 2017 | $-82.54M | 31.05% |
| 2016 | $-62.99M | -381.25% |
| 2015 | $22.40M | -529.58% |
| 2014 | $-5.21M | -135.49% |
| 2013 | $14.69M | 264.74% |
| 2012 | $4.03M | -72.78% |
| 2011 | $14.80M | -15.98% |
| 2010 | $17.61M | -5.77% |
| 2009 | $18.69M | -25.44% |
| 2008 | $25.07M | 0.00% |
| 2007 | 0.00 | -100.00% |
| 2006 | $6.96M | 15.15% |
| 2005 | $6.04M | 1,478.98% |
| 2004 | $382.53K | -107.32% |
| 2003 | $-5.22M | -79.57% |
| 2002 | $-25.56M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -1,229.80% |
US
|
|
| $-3.09B | 561.18% |
US
|
|
| $-4.02B | 760.20% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -517.80% |
NL
|
